190442-16-1

Basic information

• Product Name: Benzenemethanol, 3-hydroxy-, a-nitrate
• CAS NO: 190442-16-1
• Molecular Formula: C7H7NO4
• Molecular Weight: 169.137
• Mol File: 190442-16-1.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Benzenemethanol, 3-hydroxy-, a-nitrate(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenemethanol, 3-hydroxy-, a-nitrate(190442-16-1)
• EPA Substance Registry System: Benzenemethanol, 3-hydroxy-, a-nitrate(190442-16-1)

Safety Data

• Hazardous Substances Data: 190442-16-1(Hazardous Substances Data)

Upstream product

• 74597-04-9 m-hydroxybenzyl bromide 
• 60760-06-7 3-hydroxybenzyl chloride 
• 620-24-6 3-Hydroxybenzyl alcohol 

Downstream Products

• 685106-98-3 4-[(nitrooxy)-methyl]-phenyl {4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl}-sulfonylcarbamate 
• 1070804-77-1 3-(nitrooxymethyl)phenyl 4-(2,3-dihydro-1,3-dioxo-1H-isoindol-2-yl)benzoate 
• 691005-65-9 (+/-)-3-({3-[4-(methylsulfonyl)phenyl]-5-oxo-4-phenyl-2,5-dihydrofuran-2-yl}oxy)benzyl nitrate 

Relevant articles and documents

NITROXY DERIVATIVES OF SOFT STEROIDS

A compound of formula (I) or a pharmaceutically acceptable salt thereof, and an ophthalmic composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof. The invention is also directed to the use of the ophthalmic compositions for treating inflammatory conditions of the palpebral or bulbar conjunctiva, cornea and anterior segment of the globe, and to ameliorate inflammation associated with corneal injury.

Synthesis and biological evaluation of nitric oxide-donating thalidomide analogues as anticancer agents

In search of more potent anticancer agents, 15 nitric oxide (NO)-donating thalidomide analogues, 6a, 6b, 8a-8e, and 13a-13h, were designed and synthesized. Cytotoxicity of these compounds was evaluated in vitro against three human tumor cell lines (HepG2, A549, and PC-3). The results indicated that 13a-13d exhibited notable anticancer activities comparable to or stronger than that of 5-fluorouracil (5-FU). Structure-activity relationships were also discussed, based on the experimental data obtained. Generally, the cytotoxic activity of target compounds is closely related to the type of NO donors, and the length of the spacers connecting to NO donors also appears important for the bioactivities.

New NO-releasing pharmacodynamic hybrids of losartan and its active metabolite: Design, synthesis, and biopharmacological properties

In a preliminary work, we reported two NO-sartans, possessing the characteristics of an AT1 antagonist and a "slow NO donor", obtained by adding NO-donor side chains to losartan 1. The NO release from an NO-sartan should be modulated in order to strengthen the antihypertensive activity of the native drug and to ensure additional effects, such as the antiplatelet and anti-ischemic ones. To obtain a collection of proto-typical NO-sartans, showing different rates of NO release, new NO-donor moieties have been linked to 1 or its active metabolite 2 (EXP 3174). Almost all the synthesized compounds exhibited both AT1-antagonist and NO-mediated vasorelaxing properties, with a wide range of NO-releasing rates. Further pharmacological investigation on compound 4a showed that it possessed antihypertensive and cardiac antihypertrophic effects similar to those of the reference AT1-blocking or ACE-inhibiting drugs. Furthermore, the additional anti-ischemic cardio-protective properties and antiplatelet effects of 4a have been preliminarily investigated.